Skip to main content

AS/Spondyloarthritis

      EFFECTIVENESS & COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPA (
      2 weeks 4 days ago
      EFFECTIVENESS & COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPA (TeleSpA-STUDY): PRAGMATIC MULTICENTRE RVT cost effective but no one will ever be examined again especially for pathology outside joints! @rheumnow #EULAR2024
      Extra-musculoskeletal manifestations (EMMs) occur in patients with spondyloarthritis.The prevalence of EMMs such as uveitis, psoriasis and inflammatory bowel disease are 26%, 9% and 7% respectively…
      Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy
      2 weeks 5 days ago
      Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy @wk 48 (52%) & wk256 (50%). Low AE for candidiasis (2.6%), SIE (1.4%), IBD (0.8/100PY), Uveitis (0.7/100PY) Abst# POS0215 #EULAR2024 https://t.co/9PWey3itu9
      #Editors Picks @eular_org @ARD_BMJ @ACR_Journals

      Can #rheumatologists effectively #dx of #ankylosing #spondylitis?

      ?
      2 weeks 5 days ago
      #Editors Picks @eular_org @ARD_BMJ @ACR_Journals Can #rheumatologists effectively #dx of #ankylosing #spondylitis? đź‘Ť 552 pts - 1/3 axSpA w high certainty Certainty of #dx changed over time 2 features #sacroileitis good #nSAID response #EULAR2024 @RheumNow https://t.co/NN3GZTmgn9
      10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic dis
      2 weeks 5 days ago
      10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab.… https://t.co/HrRnoDzSPP https://t.co/Gp1KZmPych
      Increase in mSASSS over time was greater with increasing comorbidity burden. Increasing comorbidity burden is independen
      2 weeks 6 days ago
      Increase in mSASSS over time was greater with increasing comorbidity burden. Increasing comorbidity burden is independently associated with greater radiographic progression #EULAR2024 OP0103 @RheumNow https://t.co/j7UblASUvC